English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduAn analysis of 15 name-brand drugs and their “skinny label” generic counterparts found that competition from these counterparts saved Medicare Part D nearly $15 billion from 2015 to 2021.
Tag: Generic Drugs
La encuesta de ILAE destaca las preocupaciones globales sobre los medicamentos genéricos anticrisis
Los neurólogos de todo el mundo tienen preocupaciones sobre el uso de medicamentos genéricos anticrisis, cuestionando la calidad deficiente o inconsistente, el acceso limitado, el costo y la falta de control regulatorio.
La encuesta de ILAE destaca las preocupaciones globales sobre los medicamentos genéricos anticrisis
Les neurologues du monde entier s’inquiètent de l’utilisation d’antiépileptiques génériques, notamment concernant leur qualité médiocre ou inégale, leur accès restreint, leur coût, et l’absence de contrôle réglementaire.
ILAE survey highlights global concerns about generic anti-seizure medications
Neurologists worldwide have concerns about the use of generic anti-seizure medications, including poor or inconsistent quality, limited access, cost, and lack of regulatory control, according to a global survey of health care professionals.
Requests for Brand Name Over Generic Prescription Drugs Cost the Medicare Program $1.7 Billion in a Single Year, Study Finds
The Medicare Part D program would have saved $977 million in a single year if all branded prescription drugs requested by prescribing clinicians had been substituted by a generic option, according to a new study by researchers at the Johns Hopkins Bloomberg School of Public Health.